TRIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. TRIB is showing immediate downside momentum (regular session -7.38% and pre-market -5.06%), no proprietary buy signals, no near-term news catalysts, and weakening profitability despite modest revenue growth. For an impatient buyer, the risk/reward is unfavorable at current levels; better to avoid until price strength returns above resistance (~0.92) or a clear catalyst emerges.
Price/Trend: Sharp recent selloff (regular -7.38%, pre -5.06%, post ~flat), suggesting bearish near-term momentum. Momentum: MACD histogram is positive (0.0223) but positively contracting—bullish momentum is fading rather than strengthening. RSI(6) at ~44.8 sits in neutral-to-bearish territory (not oversold), implying there may be room for further downside without a strong rebound signal. Moving Averages: Converging MAs indicate a lack of strong trend support and higher uncertainty; not a clean uptrend setup. Levels: Pivot ~0.811 (current ~0.816). If price loses the pivot, next supports: S1 ~0.699 then S2 ~0.63. Upside resistance: R1 ~0.922 then R2 ~0.991. With price sitting just above pivot after a big drop, it’s a fragile setup rather than a high-conviction entry. Pattern odds: Similar-pattern projection suggests only modest expected upside (next day ~0.74%, next week ~2.22%, next month ~2%), which doesn’t compensate for the nearby downside supports if the pivot fails.
Intellectia Proprietary Trading Signals
No news in the past week (no fresh negative catalyst).
Call-heavy options open interest could indicate some market participants positioned for upside.
Gross margin improved materially in the latest reported quarter (2024/Q3), which can be constructive if sustained.
Strong near-term downside momentum (large regular and pre-market declines).
No event-driven catalyst support in recent news flow.
Extremely high implied volatility suggests the market is pricing significant uncertainty/risk.
Profitability is deteriorating (larger net loss and lower EPS YoY in latest quarter), which can pressure sentiment and financing expectations for a micro-cap biotech/diagnostics name.
Latest quarter provided: 2024/Q3. Revenue: $15.152M, +3.24% YoY (modest top-line growth). Net Income: -$4.759M, -29.19% YoY (loss widened). EPS: -0.02, -90.91% YoY (meaningfully worse). Gross Margin: 35.03%, +20.13% YoY (margin improvement is a bright spot, but not yet translating into better bottom-line results). Overall: improving margins but weakening earnings quality—mixed, leaning negative for near-term buying.
No analyst rating/price target change data was provided, so recent Wall Street upgrades/downgrades and target revisions cannot be confirmed. Without documented analyst support or improving targets, there’s no clear ‘pro’ catalyst from the Street to offset the current bearish tape.
